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Graphical Abstract
An innovative microneedle (MN)-based cell therapy is developed for glucose-responsive 
regulation of the insulin secretion from exogenous pancreatic β-cells without implantation. One 
MN patch could quickly reduce blood sugar levels (BGLs) of chemically-induced type 1 diabetic 
mice and stabilize BGLs at a reduced level for over 10 hours.
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Diabetes mellitus, as one of the most challenging chronic diseases, currently affects over 387 
million people worldwide and this number is estimated to increase to around 500 million by 
2030.[1] Providing lifelong exogenous insulin is essential for the treatment of type 1 
diabetes.[2] However, there was an estimated 4.9 million diabetes related deaths worldwide 
in 2014.[1] A key constraint of the traditional insulin injection lies in inadequate glycemic 
control, which leads to diabetes complications, such as blindness, limb amputation and 
kidney failure. Conversely, overtreatment with insulin causes hypoglycemia, which can lead 
to behavioral and cognitive disturbance, seizure, brain damage, or death.[3]
Transplantation of insulin-producing cells has been intensively explored for treating type 1 
diabetes.[4] However, due to the host recognition of transplanted cells, dependence on donor 
cells and requirement of extensive immunosuppressive therapy, direct cell implantation has a 
limited role in diabetes care.[5] An alternative technique is to encapsulate pancreatic β-cells 
in a semi-permeable container, isolating and protecting them from the immune system while 
still allowing the diffusion and transportation of nutrients and oxygen to the encapsulated 
cells.[6, 7] Nevertheless, the cell-capsule implantation or withdrawal usually requires a 
surgical procedure. More importantly, biocompatibility of the cell capsules is often 
compromised resulting in persistent inflammation, formation of foreign body giant cells, 
fibrosis, damage to the surrounding tissues and failure of the implant to control glucose.[8, 9]
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Herein, we describe a painless microneedle (MN) patch platform to modulate the insulin 
secretion from pancreatic β-cells for glucose-responsive regulation of blood glucose levels 
(BGLs) without implantation. As shown in Figure 1, this strategy integrates both live (cell-
based) and synthetic glucose-responsive systems (L-S GRS) to allow the externally 
positioned β-cell capsules to sense glucose signals and to secrete insulin through the MN in 
a minimally invasive manner. Our preliminary design only integrated cell capsules with the 
MN patch made from the crosslinked hyaluronic acid (HA) (Figure 1a). We expected that 
under a hyperglycemic state, glucose could diffuse through the MN and interact with β-cells 
encapsulated in the alginate microgels in order to promote insulin secretion. However, due to 
the limited diffusion of glucose, the patch did not effectively respond to a hyperglycemic 
state and an insignificant increase in insulin secretion was detected. To effectively trigger the 
cellular response, the MN matrix reported here specifically contains synthetic “glucose-
signal amplifiers” (GSAs) (Figure 1b). This innovative GSA is featured with self-assembled 
polymeric nanosized vesicles entrapping three enzymes: glucose oxidase (GOx), α-amylase 
(AM) and glucoamylase (GA). GOx converts glucose into gluconic acid in the presence of 
oxygen. AM hydrolyses the α-amylose into disaccharides and trisaccharides, which further 
converts to glucose by GA.[10]
Once subjected to the elevated BGLs, the GSA comprised of hypoxia-sensitive materials 
quickly disassociates to release the encapsulated enzymes in response to the rapid glucose 
oxidation by GOx and oxygen consumption:[11, 12]
The released enzymes subsequently hydrolyze α-amylose[13] embedded in the MN matrix, 
generating a local glucose-concentrated site. The “amplified” glucose effectively diffuses 
into the externally positioned β-cell capsules, promoting secretion and diffusion of insulin 
into the vascular and lymph capillary networks.[14] Using streptozotocin (STZ)-induced type 
1 diabetic mouse as an animal model, we demonstrated that the GRS consisting of ~107 β-
cells could quickly respond to a hyperglycemic state, decline and maintain BGLs at a 
reduced level for up to 10 hours. This cellular-synthetic hybrid glucose-responsive device 
with a physiological-signal amplifier modality presents a promising alternative to pancreatic 
β-cells implantation for tight regulation of BGLs.
GSA was prepared by the solvent dialysis method for encapsulating three enzymes.[15] 
Briefly, amine-functionalized 2-nitroimidazole (NI) groups were covalently conjugated to 
the HA via an amide bond. The hypoxia-sensitive HA (HS-HA) functionalized with 
hydrophobic NI groups readily self-assembled into GSAs in the aqueous solution containing 
GOx, α-amylase and amyloglucosidase (Figure S1, Supporting Information). Under a 
hypoxic condition, the hydrophobic NI groups were reduced to hydrophilic 2-
aminomidazoles via a single-electron reaction with NADPH catalyzed by 
nitroreductases.[16] The reduced product with amine groups was water-soluble, which 
facilitated the disassembly of GSA.[11, 17] The transmission electron microscopy (TEM) 
image (Figure 2a) showed that the GSA had a spherical shape with a monodisperse size. 
The average hydrodynamic size of GSA measured by dynamic light scattering (DLS) was 
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340 nm (Figure 2c), which was consistent with the TEM images. The zeta-potential of GSA 
was determined as −45.7 ± 2.4 mV due to the residual carboxyl of HA. The fluorescence 
image of GSA with fluorescein isothiocyanate (FITC)-labeled enzymes further verified 
successful co-encapsulation of the enzymes (Figure 2b). The loading capacity of GSA based 
on all the enzymes was determined as 7.4 ± 0.5 wt% and loading efficiency as 16.1 ± 1.0 wt
%. The GSA was stable when incubated at 4°C and no noticeable turbidity change was 
observed over two weeks.
To assess the glucose-responsive capability of GSA in vitro, we examined the vesicles in 
1×PBS buffer solutions with various glucose concentrations, including a typical 
hyperglycemic level (400 mg/dL), a normoglycemia level (100 mg/dL), and a control level 
(0 mg/dL). The hyperglycemia level generated a relatively lower oxygen environment in the 
GSA compared to the other two control groups, which was verified by an oxygen-sensitive 
phosphorescent molecular probe (Figure 2d). The oxygen level inside the GSA gradually 
reduced over time and reached equilibrium within 20 min. The oxygen consumption kinetics 
could be further modulated by altering the amount of GOx loaded into the vesicle, which 
showed a clearly delayed hypoxic effect with a half dose of GOx (Figure 2e). With the 
decline of oxygen level, the NI groups were effectively reduced by NADPH added into the 
solution. Correspondingly, the characteristic peak of NI at 330 nm in UV-Vis spectra 
decreased rapidly, which substantiated this bio-reduction reaction (Figure 2f). Due to the 
generation of water-soluble pendant groups on HS-HA, the GSA began to dissociate and 
subsequently release the encapsulated enzymes. As shown in TEM images, the GSA in 400 
mg/dL glucose solution experienced gradual morphology changes from 20 min to 6 h 
(Figure 2a), which was consistent with the remarkable decline in the average hydrodynamic 
size, indicated by DLS (Figure 2c). In contrast, GSA incubated with no glucose or 100 
mg/dL glucose displayed stable hydrodynamic size and no noticeable morphology change 
(Figure S2, Supporting Information). Furthermore, the release of encapsulated FITC-labeled 
enzymes from the dissociated vesicles was visualized by fluorescence microscopy. The 
fluorescence signal intensity was significantly decreased and presented homogeneous 
distribution after 2 hours, suggesting that the enzymes escaped from the dissociated GSA 
and evenly dispersed in the solution (Figure 2b).
We next analyzed the enzyme release kinetics in response to the glucose level changes. No 
significant amount of released enzymes from GSA was detected within 24 h of incubation at 
a normal glucose level (100 mg/dL) and a control level (0 mg/dL) (Figure 3a). In sharp 
contrast, a rapid enzyme release rate was achieved from the GSA in the first 2 hours at a 
hyperglycemic environment (400 mg/dL). This could be attributed to the faster reduction of 
NI groups, which was induced by the hypoxic condition upon glucose oxidation.
Afterwards, the conversion from α-amylose to glucose catalyzed by the released enzymes 
from GSA was further investigated. The encapsulation ratio of AM to GA was pre-optimized 
as 1:2 by analyzing their enzymatic hydrolysis capability of α-amylose, indicated by the 
glucose production rate (Figure S3, Supporting Information). When AM and GA were 
utilized to saccharify 10 mg/mL α-amylose solution sequentially, the glucose production 
was readily increased to 816 ± 26 mg/dL, yielding an 81.6% conversion rate of α-amylose 
(Figure S4, Supporting Information). The circulation dichroism (CD) spectra confirmed that 
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the released enzymes AM and GA from GSA maintained their secondary conformational 
structures (Figure S5, Supporting Information). Meanwhile, when the GSA was incubated in 
α-amylose solutions with various glucose concentrations, a significantly faster glucose 
production was achieved when incubated with 400 mg/dL glucose compared to the one with 
100 mg/dL glucose (Figure 3b). It indicated that the enzymatic hydrolysis of α-amylose was 
activated by the gradual release of enzymes associated with the disassembly of GSA. Taken 
together, once “sensing” the elevated glucose level, the GSA could be activated to release the 
enzymes, which promoted the α-amylose-to-glucose conversion to amplify the glucose 
signal for downstream action.
We further investigated the use of MN patches for the delivery of insulin from pancreatic β-
cell capsules. To create the “live” glucose-responsive component of the L-S GRS, the mouse 
islets β-cell lines were encapsulated in the alginate microgels with RGD[7] and type IV 
collagen[18] (packing density: 2 × 106 cell/mL) to provide a matrix with biomimetic cell-
ECM (extracellular matrix) adhesive interactions. Successful encapsulation was visualized 
by fluorescence microscopy with the concentrated cells and homogenous distribution of the 
secreted insulin surrounding the capsules (Figure 3d). The size of the obtained capsule was 
735 ± 27 μm. The glucose stimulated insulin secretion (GSIS) analysis and live-dead assay 
were performed after day 1 to day 3 to validate that the encapsulated β-cells maintained their 
viability and functionality (Figure 3e).[7] The results indicated that the encapsulated β-cells 
could survive for a relatively long period of time and maintain normal glucose-responsive 
insulin secretion capability when compared their insulin secretion index with cells cultured 
on a 2D tissue culture plate (Figure S6, Supporting Information).
Meanwhile, the MN patch was fabricated using a micromolding approach. The resulting MN 
device had 400 pyramid needles in a 10-mm2 patch, and each needle had a side length of 
400 μm at the base, a side length of 5 μm at the tip, and a height of 800 μm (Figure 3g, 3h). 
The needle was designed to have a triple-layered structure consisting of GSA, α-amylose 
and crosslinked hyaluronic acid matrix using alternating deposition. The mechanical 
strength of MN was determined as 0.18 N/needle, which was sufficient for skin penetration 
without breaking (Figure S7, Supporting Information).[19] A fluorescence view depicted the 
representative integration of MN patch with the pancreatic β-cells capsules (Figure 3i). 
GSAs were well distributed in tip region of the MNs and the cell-embedded capsules were 
positioned on the back of the MN patch.
The GSIS of L-S GRS was examined through the microfluidics (Figure 3f). The needles on 
the patch were incubated in an open microfluidic channel with continuous infusion of the 
Krebs-Ringer buffer (KRB) with a hyperglycemic level (400 mg/dL) and a normoglycemia 
level (100 mg/dL) respectively. The GSIS with the high glucose level infusion displayed a 3-
fold increase compared to the low glucose one (Figure 3c). This was attributed to the 
hyperglycemic flow, which quickly promoted the dissociation of GSA; and the subsequent 
hydrolysis of α-amylose led to an amplified, sufficient glucose level signal for triggering the 
secretion of insulin from the β-cells capsules.
To investigate the in vivo efficacy of the glucose-responsive MN device, STZ-induced type 1 
diabetic mice were subjected to transcutaneous administration of a variety of MNs samples: 
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empty MNs without GRS (w/o GRS), MNs integrated with only L-GRS (L-GRS), MNs 
integrated with only S-GRS (S-GRS), MNs integrated with L-S-GRS (L-S GRS), MNs 
integrated with L-S-GRS but without GOx in S-GRS (L-S GRS (w/o GOx)), and MNs 
integrated with L-S-GRS but without α-amylose in S-GRS (L-S GRS (w/o AM)). Each MN 
patch was administered by a homemade applicator with 5N/patch to ensure the uniform 
penetration and was immobilized on the skin by topical skin adhesive. The excised skin 
tissue clearly showed the visible sites of needle insertion (Figure 4a, top) and the 
hematoxylin and eosin (H&E)-stained cross-section image indicated that MNs could 
penetrate to a depth of approximately 200 μm to the epidermis (Figure 4a, bottom), which 
allowed the GSA to be exposed to interstitial fluid in real-time.[19]
The BGLs of treated mice in each group were monitored over time. As shown in Figure 4b, 
the BGLs in mice treated with MN patch integrated with L-S GRS quickly declined to 
nearly 200 mg/dL within two hours and maintained in a significantly reduced level for 6 h 
without peaks of hyperglycemic or hypoglycemic states. In contrast, without the complete S-
GRS (L-GRS group) or just lacking the responsive element-GOx (L-S GRS (w/o GOx) 
group) or amplifying element-AM (L-S GRS (w/o AM) group), the BGLs only decreased in 
the first hour, which could be explained by the diffusion of residual amounts of insulin 
detained in the hydrogel. Afterwards, the insulin secretion of β-cells maintained at the basal 
level and the BGLs of mice reverted to the hyperglycemic state. In the absence of β-cell 
capsules, the groups treated with MNs integrated with only S-GRS (S-GRS) or empty MN 
(w/o GRS) groups displayed no noticeable decline in BGLs as expected. The temporarily 
elevated BGLs in S-GRS group could be attributed to the induced hydrolysis of α-amylose 
and the host glucose clearance (Figure S8, Supporting Information).
To assess whether the MN patch could modulate the BGLs without causing potential risks of 
hypoglycemia, a group of STZ-induced mice were subjected to the MN patch replacement 
administration. The second MN patch treatment 6 hour post the first administration did not 
secrete excess insulin in absence of hyperglycemia trigger, which could avoid the 
hypoglycemia risk. Moreover, the additional MN patch was able to prolong the treatment 
efficiency in response to the elevated BGLs compared to the control (Figure 4c). The study 
on the healthy mice treated with MN patches integrated with L-S GRS and empty MN as 
control demonstrated that the device did not cause hypoglycemia (Figure 4d). Insignificant 
insulin release from the L-S GRS still maintained the BGLs of mice in a normal range. A 
glucose tolerance test demonstrated the tight glucose regulation capability on diabetic 
mice.[11, 20] At 2 h after administration of the L-S GRS, the diabetic mice were treated with 
an intraperitoneal glucose injection. BGLs of diabetic mice showed a 100 mg/dL increase 
and rapid decline to initial BGLs within 60 min (Figure 4e). The area under the curve 
between 0 and 120 min was calculated to indicate the MN maintenance of glucose 
homeostasis. Significant difference was observed between MN group and the control group 
2 h post glucose challenge (Figure 4f).
To assess the biocompatibility of the GSA-loaded MN patch, the cytotoxicity of dissolved 
microneedles toward β-cells was evaluated by MTT assay (Figure S9, Supporting 
Information). The MNs and corresponding dissolved products did not show significant 
decrease of cell viability with the studied concentrations. The skin treated by the MN patch 
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could rapidly recover within 8 h after MN removal and the H&E stained skin section of the 
injection site presented no obvious inflammation (Figure S10, Supporting Information).[21]
Currently, the biocompatibility and safety issues significantly hamper the clinical 
applications of pancreatic islet cells transplantation.[9, 22] Instead of utilizing traditional 
administration methods and relying on an invasive procedure, we developed a microneedle 
patch-based strategy to control the insulin secretion from externally positioned pancreatic β-
cells, triggered by the internal hyperglycemic state. Importantly, for the first time, a synthetic 
amplifier was incorporated to quickly amplify the physiological signal, in this case “glucose 
level”, for effective transport of the signal and sufficient stimulation of insulin secretion 
from the β-cells. The results of serial treatments in vivo showed the potency of the MN 
patches in tight glucose regulation for a prolonged period. This method circumvents the 
challenging issues for pancreatic cells therapy associated with immune response and long-
term efficacy. This effective administration period can be further extended by optimizing the 
density and viability of cells as well as the physicochemical properties of matrix material for 
transporting glucose and insulin. It is expected that the freshly-prepared patches with pig 
islets or stem cell-differentiated human pancreatic cells could be delivered to patients daily 
or every few days for ease of administration. Arguably more important from a fundamental 
perspective, this strategy also demonstrates the potential benefit of creating synthetic 
amplifiers for enhancing efficacy of physiological signal-responsive drug delivery systems 
when the original bio-signal is insufficient for triggering responsiveness.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Schematic of the glucose responsive system (GRS) based on a microneedle-array patch 
integrated with pancreatic β-cells and glucose signal amplifiers (GSA). a) Without GSA, 
there is insignificant insulin release from the MN patch neither in normoglycemia nor 
hyperglycemia state. The MN patch is composed of crosslinked hyaluronic acid (grey). b) 
With GSA, there is significant promoted insulin release triggered by a hyperglycemia state. 
The MN patch is composed of crosslinked hyaluronic acid embedding assembled layers of 
α-amylose and GSA (from top to bottom).
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Characterization of glucose signal amplifier (GSA). a) TEM images of enzymes-
encapsulated GSA pre-, post-incubated in 400 mg/dL glucose solution for 20 min, 2 h and 6 
h at 37°C respectively. Scale bar is 200 nm. b) (Top) Fluorescence 2.5D images of FITC-
enzymes loaded GSA solution pre- and post- incubated in 400 mg/dL glucose solution for 2 
h at 37°C. (Bottom) Distribution of the fluorescence intensity along the indicated white dash 
line. a.u., arbitrary unit. c) Size distribution of GSA pre- and post- incubated in 400 mg/dL 
glucose solution for 6 h. d) Phosphorescence lifetime profile for the GSA incubated in 
different glucose level solutions containing an oxygen concentration molecule probe. e) 
Phosphorescence lifetime profile for the GSA loaded with full or half dose of GOx in 400 
mg/dL glucose solutions. f) Intensity of UV absorption at 330 nm of GSA in solutions with 
different glucose concentrations at 37 °C. Error bars indicate standard deviation (s.d.) (n = 
3).
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In vitro glucose-responsive studies of GSA and characterization of the MN patch and L-S 
GRS. a) In vitro accumulated enzymes release profile of the GSA in solutions with different 
glucose concentrations at 37°C. *P <0.05 for GSA in 400 mg/dL glucose solution compared 
with those in 100 or 0 mg/dL glucose concentration solutions. b) Accumulated glucose 
production from the α-amylose hydrolysis catalyzed by the released enzymes. *P<0.05 for 
GSA in 400 mg/dL glucose solution compared with those in 100 or 0 mg/dL glucose 
solutions. c) Insulin secretion rate profile of L-S GRS simulated by the inflow of different 
glucose solutions through a microfluidics device (100 and 400 mg/dL). (n = 3). d) 
Immunofluorescence image of the pancreatic β-cell capsules stained with insulin (green) and 
nucleus (blue). Scale bar is 500 μm. e) (a-c) Fluorescence images of the pancreatic β-cells 
from day 1 to day 3 after the encapsulation. Cells were stained with calcium-AM (live, 
green) and ethidium homodimer (dead, red). Scale bar is 500 μm. (bottom right) The insulin 
secretion index of the cells capsules as the function of time from day 1 to day 3 after 
encapsulation. Error bars indicate s.d. (n = 3). f) Schematic of stimulated insulin secretion 
from the L-S GRS using a microfluidics device. KRB with different glucose concentration 
flowed through the microfluidics channel and insulin secreted by the pancreatic β-cell 
capsules was collected from the outlet. g) Digital pictures of the GSA-loaded MN patch. 
Scale bar is 1 cm. h) SEM image of the MN patch. Scale bar is 500 μm. i) Fluorescence 
microscopy image of the L-S GRS: MN patch was loaded with rhodamine-labeled GSA and 
calcium AM-stained pancreatic β-cell capsules were positioned on the back of the MN 
patch. Scale bar is 500 μm.
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In vivo studies of L-S GRS for type 1 diabetes treatment. a) Mouse dorsum skin was 
transcutaneously treated with MN patches. Scale bar is 1 mm (top); H&E stained cross-
section of the treated skin indicated by the area within black dashed line (bottom). The 
regions of skin muscles and fat tissues are labeled as M and F, respectively. Scale bar is 200 
μm. b) In vivo studies of the MN patches for STZ-induced type 1 diabetic mice treatment. 
Mice were subjected to transcutaneous administration with a variety of MNs samples: empty 
MNs without GRS (w/o GRS), MNs integrated with only L-GRS (L-GRS), MNs integrated 
with only S-GRS (S-GRS), MNs integrated with L-S-GRS (L-S GRS), MNs integrated with 
L-S-GRS but without GOx in S-GRS (L-S GRS (w/o GOx)), and MNs integrated with L-S-
GRS but without α-amylose in S-GRS (L-S GRS (w/o AM)). *P < 0.05 for administration 
with MN integrated with L-S GRS compared with the control groups. c) BGLs change of 
diabetic mice treated with additional MN (L-S GRS) 6 h post administration. *P <0.05 for 
additional administration with MN compared with no additional administration. The black 
arrows indicate the administration points. d) BGLs change of the healthy mice after the MN 
administration (MN L-S GRS or empty MN (MN w/o GRS)). Error bars indicate s.d. (n = 
5). e) Glucose tolerance test toward diabetic mice 2 h post administration of MNs with L-S 
GRS in comparison with the healthy control mice. The time points of administration were 
pointed out by the black arrows. f) The responsiveness was calculated based on the area 
under the curve (AUC) in 120 min, with the baseline set at the 0-min blood glucose reading. 
Error bars indicate s.d. (n = 5). *P < 0.05 for diabetic mice treated with MN L-S GRS 
administration compared to the healthy mice.
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